Clinical Trials Browser

UNKNOWN × Squamous Cell Carcinoma of Head and Neck × Clear all

NCT04740996 2022-02-07

Study of Pembrolizumab in the First Line Therapy for R/M HNSCC in China

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05202275 2022-01-21

The Optimization of Antiemetic Regimen for C-RINV in LA-HNSCCs

Phase 2 Unknown

Squamous Cell Carcinoma of Head and Neck, Nausea, Radiation Injuries, Vomiting

NCT05136768 2021-11-29

LM-HNSCC

Phase 2 Unknown

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis

NCT04999800 2021-08-11

Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1

Phase 2 Unknown

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04861467 2021-04-27

Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

Phase 2 Unknown

Squamous Cell Carcinoma of Head and Neck

NCT03744208 2018-11-16

SCT200 Injection in Patients With Head and Neck Squamous Cell Carcinoma

Phase 2 Unknown

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT01975688 2016-08-11

A Pharmacokinetic Study of Single Doses of Sativex in Treatment-induced Mucositis

Phase 1 Terminated

Squamous Cell Carcinoma of Head and Neck